DRMA vs. TSBX, BLRX, JAGX, MBIO, EYEN, AWH, PMCB, PHXM, AYTU, and KPRX
Should you be buying Dermata Therapeutics stock or one of its competitors? The main competitors of Dermata Therapeutics include Turnstone Biologics (TSBX), BioLineRx (BLRX), Jaguar Health (JAGX), Mustang Bio (MBIO), Eyenovia (EYEN), Aspira Women's Health (AWH), PharmaCyte Biotech (PMCB), PHAXIAM Therapeutics (PHXM), Aytu BioPharma (AYTU), and Kiora Pharmaceuticals (KPRX). These companies are all part of the "pharmaceutical products" industry.
Dermata Therapeutics vs.
Dermata Therapeutics (NASDAQ:DRMA) and Turnstone Biologics (NASDAQ:TSBX) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, community ranking, institutional ownership, media sentiment, valuation, risk, earnings, analyst recommendations and profitability.
Dermata Therapeutics has a beta of 0.66, indicating that its share price is 34% less volatile than the S&P 500. Comparatively, Turnstone Biologics has a beta of 2.14, indicating that its share price is 114% more volatile than the S&P 500.
Dermata Therapeutics received 1 more outperform votes than Turnstone Biologics when rated by MarketBeat users.
8.7% of Dermata Therapeutics shares are owned by institutional investors. Comparatively, 52.5% of Turnstone Biologics shares are owned by institutional investors. 4.3% of Dermata Therapeutics shares are owned by company insiders. Comparatively, 32.1% of Turnstone Biologics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Dermata Therapeutics has higher earnings, but lower revenue than Turnstone Biologics. Turnstone Biologics is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks.
Turnstone Biologics' return on equity of -105.99% beat Dermata Therapeutics' return on equity.
Dermata Therapeutics presently has a consensus target price of $6.00, indicating a potential upside of 352.83%. Turnstone Biologics has a consensus target price of $2.13, indicating a potential upside of 364.99%. Given Turnstone Biologics' higher possible upside, analysts plainly believe Turnstone Biologics is more favorable than Dermata Therapeutics.
In the previous week, Dermata Therapeutics had 1 more articles in the media than Turnstone Biologics. MarketBeat recorded 2 mentions for Dermata Therapeutics and 1 mentions for Turnstone Biologics. Dermata Therapeutics' average media sentiment score of 0.00 equaled Turnstone Biologics'average media sentiment score.
Summary
Turnstone Biologics beats Dermata Therapeutics on 8 of the 13 factors compared between the two stocks.
Get Dermata Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DRMA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dermata Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:DRMA) was last updated on 1/21/2025 by MarketBeat.com Staff
Free DRMA Stock Alerts